Accuracy of Sentinel Lymph Node Biopsy in Nodal Staging of High Risk Endometrial Cancer: A Prospective Trial
The standard of care for women with high risk endometrial cancer is the removal of all
visible lymph nodes in the pelvis and lower abdomen to identify if disease has spread to
these areas. It is estimated that no more than 25% of all women with presumed early stage
high risk endometrial cancer will have positive lymph nodes however currently the majority
of women are subjected to extensive resection of all pelvic lymph and or para-aortic lymph
nodes and its associated morbidities. The objective of this study is to determine if
intraoperative sentinel lymph node (SLN) mapping will improve the assessment of regional
lymph nodes and enhance the detection of lymph nodes with metastatic disease in endometrial
cancer. This would benefit the majority of women with early stage high risk endometrial
cancer and would prevent the associated complications of pelvic lymph node dissection.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society